WESTON, Fla. - Research from the University of Miami Miller School of Medicine, published in the peer-reviewed journal Frontiers in Molecular Neuroscience, has found a link between inflammasome-mediated inflammation in Alzheimer's disease (AD) and cardiovascular inflammation. The study, funded by ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), indicates that extracellular vesicles (EVs) laden with inflammasome proteins can cause significant inflammation in cardiovascular cells.
The research highlights that inflammasomes, particularly NLRP1 and pyrin, are significantly elevated in the cortex of AD mice. These inflammasomes release EVs containing inflammatory proteins into the bloodstream, which, when transferred to cardiovascular cells, can induce a heightened inflammatory response.
Juan Pablo de Rivero Vaccari, an associate professor at the University of Miami, stated, "Our data provide evidence that there is a neural-cardiac axis mediated by EVs in AD." He suggests that targeting inflammasomes could be a novel approach to treating cardiac comorbidities in AD patients.
ZyVersa is developing an Inflammasome ASC Inhibitor, IC 100, as a potential therapeutic agent. IC 100 is a monoclonal antibody designed to inhibit the formation of multiple types of inflammasomes, thereby reducing the initiation and spread of damaging inflammation. Stephen C. Glover, CEO of ZyVersa, commented on the importance of attenuating activation of inflammasomes to control systemic inflammatory signals.
Alzheimer's disease affects approximately 6.7 million people in the United States and is often associated with heart disease and stroke, leading to increased morbidity and mortality. The findings of this study underscore the potential for IC 100 to address the inflammatory aspects of AD and its comorbidities.
ZyVersa is advancing IC 100 through its development pipeline, focusing on inflammatory and renal diseases. The company aims to leverage its proprietary technologies to meet the unmet medical needs of patients with these conditions.
This article is based on a press release statement and reflects the current stage of ZyVersa's research and development efforts for IC 100. It does not constitute an endorsement of the company's claims or its future prospects.
InvestingPro Insights
As ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) continues to advance its Inflammasome ASC Inhibitor, IC 100, through the development pipeline, the financial health and market sentiment around the company provide a crucial backdrop for investors. According to real-time data from InvestingPro, ZyVersa holds a market capitalization of $3.79 million USD, which indicates its size within the biotech sector. Despite the company's focus on addressing significant medical needs, analysts are not optimistic about its profitability in the near term.
InvestingPro Tips for ZyVersa suggest that the company is currently navigating through challenging times. The stock is considered to be in oversold territory according to the Relative Strength Index (RSI), which could attract investors looking for potential bargains. However, the company's stock has experienced a substantial decline over the last week, month, and six months, with a one-week price total return of -13.19% and a six-month price total return of -87.04%. This performance reflects the market's reaction to both the company's financial health and its operational progress.
InvestingPro also highlights that ZyVersa has more cash than debt on its balance sheet, which is a positive sign for its financial stability. Nonetheless, the company's short-term obligations exceed its liquid assets, suggesting potential liquidity challenges ahead. With no dividend payouts to shareholders, the investment case for ZyVersa is primarily growth-focused, hinging on the successful development and potential market adoption of its IC 100 therapy.
For those considering an investment in ZyVersa or seeking a deeper analysis of the company's prospects, there are additional InvestingPro Tips available. By visiting https://www.investing.com/pro/ZVSA, investors can access these insights and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. Currently, there are 13 additional tips listed in InvestingPro that could provide further guidance on whether ZyVersa represents a sound investment opportunity at this stage in its development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.